Skip to main content
. 2020 Sep 11;15:108. doi: 10.1186/s13000-020-01030-x

Fig. 2.

Fig. 2

Percentages of patients with CgA-variation at different primary tumor sites (a). Percentages of patients with CgA-variation under different classifications of NENs (b). Percentages of patients with CgA-variation under different types of metastatic tumors (c)